BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

JERUSALEM, Israel--(BUSINESS WIRE)--BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology. The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, th

Feed Date: 
February 21, 2012